Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by George, T. P. Articles by Kosten, T. R. Search for Related Content PubMed Citation Articles by George, T. P. Articles by Kosten, T. R. Nicotine Schizophrenia Spectrum Disorders Other Psychotherapy Other Neuroleptics Other Somatic Therapy

Nicotine Transdermal Patch and Atypical Antipsychotic Medications for Smoking Cessation in Schizophrenia

OBJECTIVE: Schizophrenic patients have high rates of cigarette smoking. The authors compared the outcomes of two group psychotherapy programs for smoking cessation in patients with schizophrenia or schizoaffective disorder who were also treated with the nicotine transdermal patch and with either atypical or typical antipsychotic medications. METHOD: Forty-five subjects were randomly assigned to 1) the group therapy program of the American Lung Association (N=17) or 2) a specialized group therapy program for smokers with schizophrenia (N=28) that emphasized motivational enhancement, relapse prevention, social skills training, and psychoeducation. All subjects participated in 10 weeks of treatment with the nicotine transdermal patch (21 mg/day) and 10 weekly group therapy sessions and continued to receive their prestudy atypical (N=18) or typical (N=27) antipsychotic medications. Outcome variables included treatment retention, rate of smoking abstinence, and expired-breath carbon monoxide level. RESULTS: Smoking abstinence rates did not differ in the two group therapy programs. However, atypical antipsychotic agents, in combination with the nicotine transdermal patch, significantly enhanced the rate of smoking cessation (55.6% in the atypical agent group versus 22.2% in the typical group), which was reflected by a significant effect of atypical versus typical agents on carbon monoxide levels. Risperidone and olanzapine were associated with the highest quit rates. CONCLUSIONS: The results suggest that 1) smoking cessation rates with the nicotine transdermal patch are modest in schizophrenia, 2) specialized group therapy for schizophrenic patients is not significantly different from American Lung Association group therapy in its effect on smoking cessation, and 3) atypical agents may be superior to typical agents in combination with the nicotine transdermal patch for smoking cessation in schizophrenia.

This article has been cited by other articles:

				T. L Purvis, S. E Mambourg, T. M Balvanz, H. E Magallon, and R. H Pham Safety and Effectiveness of Varenicline in a Veteran Population with a High Prevalence of Mental Illness Ann. Pharmacother., May 1, 2009; 43(5): 862 - 867. [Abstract] [Full Text] [PDF]

				L. Borras, S. Mohr, P.-Y. Brandt, C. Gillieron, A. Eytan, and P. Huguelet Influence of Spirituality and Religiousness On Smoking Among Patients With Schizophrenia or Schizo-Affective Disorder in Switzerland International Journal of Social Psychiatry, November 1, 2008; 54(6): 539 - 549. [Abstract] [PDF]

				J. Campion, K. Checinski, and J. Nurse Review of smoking cessation treatments for people with mental illness Adv. Psychiatr. Treat., May 1, 2008; 14(3): 208 - 216. [Abstract] [Full Text] [PDF]

				J. Campion, K. Checinski, J. Nurse, and A. McNeill Smoking by people with mental illness and benefits of smoke-free mental health services Adv. Psychiatr. Treat., May 1, 2008; 14(3): 217 - 228. [Abstract] [Full Text] [PDF]

				A. I. Green, R. E. Drake, M. F. Brunette, and D. L. Noordsy Schizophrenia and Co-Occurring Substance Use Disorder Am J Psychiatry, March 1, 2007; 164(3): 402 - 408. [Full Text] [PDF]

				J. M. Williams and J. Foulds Successful Tobacco Dependence Treatment in Schizophrenia Am J Psychiatry, February 1, 2007; 164(2): 222 - 227. [Full Text] [PDF]

				A. Baker, R. Richmond, M. Haile, T. J. Lewin, V. J. Carr, R. L. Taylor, S. Jansons, and K. Wilhelm A Randomized Controlled Trial of a Smoking Cessation Intervention Among People With a Psychotic Disorder Am J Psychiatry, November 1, 2006; 163(11): 1934 - 1942. [Abstract] [Full Text] [PDF]

				W. H. Berrettini and C. E. Lerman Pharmacotherapy and Pharmacogenetics of Nicotine Dependence Am J Psychiatry, August 1, 2005; 162(8): 1441 - 1451. [Abstract] [Full Text] [PDF]

				M. McFall, A. J. Saxon, C. E. Thompson, D. Yoshimoto, C. Malte, K. Straits-Troster, E. Kanter, X.-H. A. Zhou, C. M. Dougherty, and B. Steele Improving the Rates of Quitting Smoking for Veterans With Posttraumatic Stress Disorder Am J Psychiatry, July 1, 2005; 162(7): 1311 - 1319. [Abstract] [Full Text] [PDF]

				K. A. Sacco, A. Termine, A. Seyal, M. M. Dudas, J. C. Vessicchio, S. Krishnan-Sarin, P. I. Jatlow, B. E. Wexler, and T. P. George Effects of Cigarette Smoking on Spatial Working Memory and Attentional Deficits in Schizophrenia: Involvement of Nicotinic Receptor Mechanisms Arch Gen Psychiatry, June 1, 2005; 62(6): 649 - 659. [Abstract] [Full Text] [PDF]

				J. FOULDS and J. WILLIAMS Tobacco Use and Cataracts in Patients With Schizophrenia Am J Psychiatry, May 1, 2005; 162(5): 1028 - 1028. [Full Text] [PDF]

				M. C. Aguilar, M. Gurpegui, F. J. Diaz, and J. De Leon Nicotine dependence and symptoms in schizophrenia: Naturalistic study of complex interactions The British Journal of Psychiatry, March 1, 2005; 186(3): 215 - 221. [Abstract] [Full Text] [PDF]

				W. J. O'Donnell, R. L. Kradin, A. E. Evins, and C. Wittram Case 39-2004 - A 52-Year-Old Woman with Recurrent Episodes of Atypical Pneumonia N. Engl. J. Med., December 23, 2004; 351(26): 2741 - 2749. [Full Text] [PDF]

				A. R. Lingford-Hughes, S. Welch, and D. J. Nutt Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology J Psychopharmacol, September 1, 2004; 18(3): 293 - 335. [PDF]

				I. Kagan, R. Kigli-Shemesh, N. Tabak, M. Z Abramowitz, and J. Margolin Patient Rights and Law: tobacco smoking in psychiatric wards and the Israeli Prevention of Smoking Act Nursing Ethics, September 1, 2004; 11(5): 472 - 478. [Abstract] [PDF]

				J. C Negrete History of alcohol abuse reduces response to antipsychotics in people with first episode psychosis Evid. Based Ment. Health, August 1, 2004; 7(3): 87 - 87. [Full Text] [PDF]

				B. Spring, R. Pingitore, and D. E. McChargue Reward Value of Cigarette Smoking for Comparably Heavy Smoking Schizophrenic, Depressed, and Nonpatient Smokers Am J Psychiatry, February 1, 2003; 160(2): 316 - 322. [Abstract] [Full Text] [PDF]

				N. el-Guebaly, J. Cathcart, S. Currie, D. Brown, and S. Gloster Smoking Cessation Approaches for Persons With Mental Illness or Addictive Disorders Psychiatr Serv, September 1, 2002; 53(9): 1166 - 1170. [Abstract] [Full Text] [PDF]

				A. H. Glassman and J. T. Bigger Jr. Antipsychotic Drugs: Prolonged QTc Interval, Torsade de Pointes, and Sudden Death Am J Psychiatry, November 1, 2001; 158(11): 1774 - 1782. [Abstract] [Full Text] [PDF]

				Treatments for Smoking in Schizophrenic Patients Journal Watch Psychiatry, December 19, 2000; 2000(1219): 5 - 5. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2000 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us